Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.

ABSTRACT:

Objectives

We sought to determine the safety and efficacy of the oral androgen receptor antagonist enzalutamide in patients with previously treated, recurrent, AR-positive (AR+) ovarian cancer.

Methods

This was a single-institution phase II study of patients with AR+ ovarian cancer with measurable disease with 1-3 prior lines of chemotherapy; patients were screened for enrollment from 11/2013-7/2018. Following consent, archival tissue was evaluated for AR+. Enrolled patients received daily enzalutamide 160 mg until progression of disease or treatment discontinuation. Adverse events were graded by CTCAE v4.0. Co-primary endpoints were 6-month progression-free survival (PFS₆) and overall response rate (ORR) by RECIST 1.1 criteria.

Results

During the study per

SUBMITTER: Manning-Geist BL 

PROVIDER: S-EPMC9449573 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature